anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
TRACS is an all-comer, prospective, randomized, multicenter, open-label trial with blinded adjudicated evaluation of outcomes (PROBE). The TRACS trial will involve centers without on-site cardiac surgery, but with experienced operators already performing TAVI at the referring center with on-site cardiac surgery. Thus, participating centers and their study TAVI operators must follow selective criteria for eligibility. Participants will be recruited after Heart Team indication to TAVI procedure. The eligibility of each single patient to the study MUST BE CONFIRMED and VALIDATED by unanimous decision of the Heart Team. Study patients will be randomized in a 2:1 fashion to TAVI procedure performed by the same experienced operators either in the center without on-site cardiac surgery or in the referring center with on-site cardiac surgery.
Nilotinib was administered orally at 300 mg BD at approximately 12 hour intervals which had to be taken without food. The capsules were to be swallowed whole with water and no food should have been consumed for at least 2 hours before and at least 1 hour after the dose was taken. Prior to the first dose of nilotinib, patients were required to have an imatinib or dasatinib washout period of at least 3 days. Therapy with nilotinib was to be continued for up to 24 months while on study.
Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with stable disease receive a maximum of 6 courses. Patients with partial response receive a maximum of 12 courses. Patients with CR receive 2 additional courses beyond CR.
BACKGROUND: Predictors of the outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remain to be fully determined. We evaluated selected viral characteristics and immunological responses that might predict and/or correlate to the clinical outcome of COVID-19.
METHODS: For individuals developing divergent clinical outcomes, the magnitude and breadth of T cell-mediated responses were measured within 36 h of symptom onset. Peripheral Blood Mononuclear Cells (PBMCs) were subjected to in vitro stimulation with SARS-CoV-2-based peptides. In addition, SARS-CoV-2 sequences were generated by metagenome, and HLA typing was performed using Luminex technology.
FINDINGS: CD4+ T cell activation was negatively correlated with SARS-CoV-2 basal viral load in patients with severe COVID-19 (p = 0·043). The overall cellular immune response, as inferred by the IFN-γ signal, was higher at baseline for patients who progressed to mild disease compared to patients who progressed to severe disease (p = 0·0044). Subjects with milder disease developed higher T cell responses for MHC class I and II-restricted peptides (p = 0·033).
INTERPRETATION: Mounting specific cellular immune responses in the first days after symptom onset, as inferred by IFN-γ magnitude in the ELISPOT assay, may efficiently favor a positive outcome. In contrast, progression to severe COVID-19 was accompanied by stronger cellular immune responses, higher CD4 + T cell activation, and a higher number of in silico predicted high-affinity class I HLA alleles.
The invention discloses feed additives for preventing and treating duck enteritis and a preparation method and application of the feed additives and belongs to the field of duck enteritis treating. The feed additives for preventing and treating the duck enteritis comprise radix gentianae, radix angelicae dahuricae, polygonum bistorta, cimicifugae foetida, rhizoma atractylodis, Corydalis ambigua Cham. et Schlecht., mangnolia officinalis, folium sennae, papaya, hawthorn, geranium wilfordii, viola philippica, hedyotis diffusa, agastache rugosus, sonchus brachyotus, chelidonium majus, snokeweed, barley malt and EM bacterial liquid. When radix pueraiae and great willowherb root are added on the basis of the feed additives, duck enteritis cure rate can be increased evidently, and the cure rate can reach more than 96%. In addition, the feed additives can effectively prevent the duck enteritis and promote duck growth. The feed additives are rich in raw material source, low in preparation cost and suitable for industrial production.
Patients receive cabozantinib PO QD and pamiparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
A user device may receive video associated with a patient, wherein the video depicts physiological activity involving the patient. The user device may receive profile information associated with the patient. The user device may obtain, from the video, image data using an image processing model. The user device may analyze the image data to generate a patient signature associated with the image data, wherein the patient signature is representative of the physiological activity. The user device may access a reference data structure that includes a plurality of reference signatures. The user device may identify that the patient signature is associated with a reference signature of the plurality of reference signatures, wherein the reference signature is associated with a health condition. The user device may perform an action associated with the health condition and the patient.
PURPOSE: A pharmaceutical composition containing Evodia fructus extract is provided to suppress cell adhesion which is mediated with ICAM-1 and LFA-1 and prevent and treat infectious diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating infectious diseases by inflammatory diseases, rhinovirus, or HIV-1 contains an Evodia fructus extract and fraction or compound isolated from the extract and fraction. The Evodia fructus extract is obtained by water, low alcohol of 1-4 carbon atoms, or their mixture solvent. The low alcohol solvent is methanol, ethanol, or butanol. The Evodia fructus fraction is obtained by fractioning with hexane, chloroform, or ethylacetate. The Evodia fructus extract contained a compound of chemical formula 1 or 2.
OBJECTIVES: I. Compare the efficacy of a busulfan containing conditioning regimen versus a total body irradiation (TBI) containing regimen for children with acute lymphoblastic leukemia (ALL) undergoing allogeneic bone marrow transplantation. II. Compare relapse rate between a chemotherapy only regimen versus a total body irradiation containing regimen for children with ALL. III. Assess and compare the acute and chronic neuropsychological effects of bone marrow transplantation (BMT) in children undergoing BMT with busulfan or TBI conditioning regimens. IV. Assess and compare the cardiac, pulmonary and growth effects of BMT in children undergoing this conditioning regimen. V. Assess the relationship between plasma busulfan levels and relapse and toxicity. VI. Assess and compare minimal residual disease patterns by quantitative polymerase chain reaction (PCR) in patients receiving busulfan or TBI conditioning regimens.

OUTLINE: This is a multicenter, randomized study comparing a chemotherapy only arm, including busulfan, with a TBI containing arm. Arm I patients receive TBI on days -7, -6, and -5 given in 2 fractions daily. Arm II patients receive busulfan every 6 hours on days -8, -7, -6, and -5. Both regimens are followed by etoposide over 4 hours on day -4 and cyclophosphamide intravenously (IV) on days -3 and -2. Marrow infusion begins following a day of rest. Starting on day -1, cyclosporine IV is administered every 12 hours or by continuous infusion and continues until day 50. Methotrexate IV is administered on days 1, 3, and 6

PROJECTED ACCRUAL: A total of 230 patients will be entered into this study.
The proposed project, Nutrition Ed, Access and Texting (NEAT): Combining the Hartford Mobile Market with e-Marketing uses an e-technology social marketing strategy to promote use of a recently launched mobile produce market among SNAP-Ed recipients. This study will potentially increase fresh produce access and intake by combining an innovative food system change (produce mobile market) with existing SNAP-Ed nutrition education curriculum and the use of e-marketing technology. Thus, the study combines key elements that have been deemed necessary for increasing produce intake among low income communities. The goal of the NEAT study is to assess the impact of a texting-based social marketing campaign on SNAP-Ed participants' access to and purchase of fresh produce on a recently launched mobile produce market, and their subsequent produce intake. Objectives include: 1) Compare the impact of nutrition education alone to nutrition education plus promotional text messaging on purchase of fruits and vegetables; 2) Compare the impact of nutrition education alone to nutrition education plus promotional text messaging on consumption of fruits and vegetables; and 3) Assess the effectiveness of coupon distribution on coupon redemption at a mobile produce market. The NEAT design will be a randomized controlled trial using a pre-post assessment comparing change in behavior. Both intervention and control groups will receive SNAP-Ed education as currently delivered by the Hispanic Health Council. The intervention group will receive additional promotional text messaging related to use of the mobile market. The control group will receive text messaging about free activities taking place at the Hartford Public Library and other community locations. Participants will be interviewed via phone at baseline, then randomized to intervention and control groups, and re-interviewed again 6 weeks after they start receiving the text messages, which it will be 2 weeks after the one-month texting period ends.
This study will determine if an interaction occurs between the HIV medicine raltegravir and an antacid. A prior study found an interaction with another medicine like raltegravir called elvitegravir and an antacid. The elvitegravir levels were reduced by half. The same interaction may occur with raltegravir and an antacid based on the structure of this medicine and how it works. When the levels of HIV medications are reduced, people with HIV can "fail" their treatment. The virus can multiply when the drug levels are too low and the medications can stop working. We need to be sure that antacids will not cause this problem with raltegravir.
Azelastine hydrochloride has been shown to cause developmental toxicity. Treatment of mice with an oral dose of 68.6 mg/kg (approximately 280 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis) caused embryo-fetal death, malformations (cleft palate; short or absent tail; fused, absent or branched ribs), delayed ossification and decreased fetal weight. This dose also caused maternal toxicity as evidenced by decreased body weight. Neither fetal nor maternal effects occurred at a dose of 3 mg/kg (approximately 10 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis). 

In rats, an oral dose of 30 mg/kg (approximately 240 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis) caused malformations (oligo-and brachydactylia), delayed ossification and skeletal variations, in the absence of maternal toxicity. At 68.6 mg/kg (approximately 560 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis) azelastine hydrochloride also caused embryo-fetal death and decreased fetal weight; however, the 68.6 mg/kg dose caused severe maternal toxicity. Neither fetal nor maternal effects occurred at a dose of 3 mg/kg (approximately 25 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis). 

In rabbits, oral doses of 30 mg/kg and greater (approximately 500 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis) caused abortion, delayed ossification and decreased fetal weight; however, these doses also resulted in severe maternal toxicity. Neither fetal nor maternal effects occurred at a dose of 0.3 mg/kg (approximately 5 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis). 

There are no adequate and well-controlled clinical studies in pregnant women. Azelastine hydrochloride nasal solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
BACKGROUND: Familial hypercholesterolemia (FH), while highly prevalent, is a significantly underdiagnosed monogenic disorder. Improved detection could reduce the large number of cardiovascular events attributable to poor case finding. We aimed to assess whether machine learning algorithms outperform clinical diagnostic criteria (signs, history, and biomarkers) and the recommended screening criteria in the United Kingdom in identifying individuals with FH-causing variants, presenting a scalable screening criteria for general populations.
METHODS AND RESULTS: Analysis included UK Biobank participants with whole exome sequencing, classifying them as having FH when (likely) pathogenic variants were detected in their LDLR, APOB, or PCSK9 genes. Data were stratified into 3 data sets for (1) feature importance analysis; (2) deriving state-of-the-art statistical and machine learning models; (3) evaluating models' predictive performance against clinical diagnostic and screening criteria: Dutch Lipid Clinic Network, Simon Broome, Make Early Diagnosis to Prevent Early Death, and Familial Case Ascertainment Tool. One thousand and three of 454 710 participants were classified as having FH. A Stacking Ensemble model yielded the best predictive performance (sensitivity, 74.93%; precision, 0.61%; accuracy, 72.80%, area under the receiver operating characteristic curve, 79.12%) and outperformed clinical diagnostic criteria and the recommended screening criteria in identifying FH variant carriers within the validation data set (figures for Familial Case Ascertainment Tool, the best baseline model, were 69.55%, 0.44%, 65.43%, and 71.12%, respectively). Our model decreased the number needed to screen compared with the Familial Case Ascertainment Tool (164 versus 227).
CONCLUSIONS: Our machine learning-derived model provides a higher pretest probability of identifying individuals with a molecular diagnosis of FH compared with current approaches. This provides a promising, cost-effective scalable tool for implementation into electronic health records to prioritize potential FH cases for genetic confirmation.
A note automation server automatically generates medical notes for appointments between patients and physicians. The note automation server generates a fingerprint for each upcoming appointment between a patient and physician using information from an EHR system and information stored on the note automation server. The fingerprint includes information about the patient, including demographic information and medical history. The note automation server identifies an appropriate note template and billing codes for the appointment using the fingerprint and an audio file recorded by a physician during and/or after an appointment. The fingerprint, audio file, and note template are used complete of the medical note. The completed medical note and billing codes are exported to the EHR system, where it is accessed by the physician. The note automation server monitors the EHR system to see if the physician modified the medical note or a billing code.
The National Institutes of Health (NIH)-sponsored Patient-Reported Outcomes Measurement Information System (PROMIS) network has developed over 20 pediatric instruments, both child-report and parent-proxy editions. Cross-sectional evaluations of the validity of the instruments have established that they are ready for integration into clinical research and practice. The next step in their ongoing evaluation is to assess their prospective clinical validity in a variety of health conditions. This study addresses the clinical evaluation of the measures in children with chronic kidney disease (CKD).

Through baseline surveys and six follow-up surveys over a two-year period, Investigators are collecting self-report (child) and parent-proxy report of 11 pediatric PROMIS measures. Each of these PROMIS measures is described in the Main Outcome Measures section. Investigators are also collecting assessments of disease activity from clinical data. The selection of self-report and parent proxy patient-reported outcome (PRO) measures were determined through qualitative content validation. The analytic goal of this project is to evaluate baseline (cross-sectional) and longitudinal associations between PROMIS pediatric outcome measures and changes in the clinical status of patients with CKD. Our primary hypothesis is that as kidney function declines, self-reported health will worsen.
PROBLEM TO BE SOLVED: To obtain a microcapsule having an org. wall film encapsulating a volatile substance and to accurately and properly control the releasing rate of the volatile substance without depending on the environment for use such as temp. by encapsulating titanium oxide and/or coating the microcapsule with titanium oxide. SOLUTION: The microcapsule having an org. wall film which encapsulates a volatile substance contains titanium oxide and/or is coated with titanium oxide. The releasing rate of the volatile substance is controlled by irradiating the microcapsule with UV rays. In the production, titanium oxide is mixed in a slurry of the microcapsule to coat the outer surface of the wall film of the microcapsule, or titanium oxide is encapsulated with the volatile substance in the microcapsule. As a result, when the microcapsule is irradiated with UV rays, the titanium oxide develops the function as a photocatalyst to decompose org. substances by active oxygen or the like. Thus, the releasing rate of the encapsulated volatile substances can be accurately and properly controlled.
Genetic factors contribute to the susceptibility of psychotic disorders, but less is known how they affect psychotic disease-course development. Utilizing polygenic scores (PGSs) in combination with longitudinal healthcare data with decades of follow-up we investigated the contributing genetics to psychotic disease-course severity and diagnostic shifts in the SUPER-Finland study, encompassing 10 403 genotyped individuals with a psychotic disorder. To longitudinally track the study participants' past disease-course severity, we created a psychiatric hospitalization burden metric using the full-coverage and nation-wide Finnish in-hospital registry (data from 1969 and onwards). Using a hierarchical model, ranking the psychotic diagnoses according to clinical severity, we show that high schizophrenia PGS (SZ-PGS) was associated with progression from lower ranked psychotic disorders to schizophrenia (OR = 1.32 [1.23-1.43], p = 1.26e-12). This development manifested already at psychotic illness onset as a higher psychiatric hospitalization burden, the proxy for disease-course severity. In schizophrenia (n = 5 479), both a high SZ-PGS and a low educational attainment PGS (EA-PGS) were associated with increased psychiatric hospitalization burden (p = 1.00e-04 and p = 4.53e-10). The SZ-PGS and the EA-PGS associated with distinct patterns of hospital usage. In individuals with high SZ-PGS, the increased hospitalization burden was composed of longer individual hospital stays, while low EA-PGS associated with shorter but more frequent hospital visits. The negative effect of a low EA-PGS was found to be partly mediated via substance use disorder, a major risk factor for hospitalizations. In conclusion, we show that high SZ-PGS and low EA-PGS both impacted psychotic disease-course development negatively but resulted in different disease-course trajectories.
Hypno-breastfeeding, which is a mind-body program that helps to increase breast milk production, is a therapy that includes emotion control, pain management, and positive suggestions that define the mother's role in the breastfeeding process. This method, in comfortable, calm and natural conditions, is effective in increasing the amount of milk by eliminating phobias, anxiety and negative thoughts in the mind of the mother, relaxing and concentrating on breastfeeding. The solution-oriented approach, on the other hand, is a therapeutic counseling practice that does not deal with the problem itself, but focuses on the past successes of the individual and the times when they did not experience the problem. In solution-oriented approach, which argues that each individual can solve their problems with their own internal resources by only directing them to the positive, it focuses on the strengths of the person instead of underlining the weaknesses. No study has been found on the effect of solution-oriented approach on breastfeeding process in the perinatal period. However, there are studies that show that the application of solution-oriented approach, which will make a different contribution to midwifery philosophies, is effective in reducing the fear of birth and reducing the anxiety of mothers who have anxiety about premature baby care. It is thought that with the effective use of the hypno-breastfeeding method and solution-oriented approach by midwives and health personnel, the perception of insufficient milk of mothers during the breastfeeding process can be reduced and breastfeeding motivation will be positively affected. In this context, this study aimed to determine the effect of hypno-breastfeeding and solution-oriented approach on breastfeeding motivation and insufficient milk perception.
A nicotine candy is provided for consumption in small volumes and in a cigarette shaped package. Each portion of the candy is obtained by removing it from a cigarette shaped package from the end. In a first embodiment, standard paper is used to wrap the a series of linearly disposed candy portions. In a second embodiment, the package is made of edible rice paper, and may be torn off of the end in a single piece. The formulation of the candy preferably uses a food grade Beta-pyridyl-alpha-N-methylpyrrolidine dissolved into any standard hard sugar candy. This material is water soluble and is admixed into the sugar candy composition during candy formation. Preferably, the candy composition is available in a range of strengths which further enables users to regulate their doses. One or two or three pieces can be ingested simultaneously to enable control of the intake, in addition to the availability of the composition in different strengths.
Albendazole and praziquantel. Albendazole: 15 mg/k/d up to 800 mg/d (days 1 to 20), followed by 15 mg/k/d up to 1200 mg/d (day 21 to 30) and prazicuantel (50 mg/k/d days 1 to 15).
The present invention provides novel polypeptides and other factors identified as being expressed in spleen tissue and related to lymphocyte activity and the immune response. These compounds are referred to herein as SPEX compounds. Human and murine homologues of SPEX polypeptides and polynucleotides are provided including two murine alleles. The invention further provides polynucleotides encoding the polypeptides and complementary nucleic acid sequences thereof. Also provided are immunogens, expression vectors, and antibodies related to the SPEX polypeptides and polynucleotides. The present invention discloses the use of anti-SPEX antibodies in the regulation of lymphocyte activity and the regulation of the immune response.
Treatment wiil be given twice a week as individual treatment by the physiotherapist. The duration of treatment is about 30 min.